| Quarter | Score |
|---|---|
| 2022-Q3 | 65.5 |
| 2022-Q4 | 50.0 |
| 2023-Q1 | 49.1 |
| 2023-Q2 | 63.4 |
| 2023-Q3 | 48.2 |
| 2023-Q4 | 36.0 |
| 2024-Q1 | 45.3 |
| 2024-Q2 | 44.5 |
| 2024-Q3 | 87.5 |
| 2024-Q4 | 85.0 |
| 2025-Q1 | 85.9 |
| 2025-Q2 | 85.7 |
| 2025-Q3 | 85.7 |
| 2025-Q4 | 85.8 |
| 2026-Q1 | 85.8 |
| 2026-Q2 | 86.0 |
High consensus with active accumulation at an attractive valuation
Within 8.9% of funds' estimated purchase price
2 of 18 tracked funds hold GWRE. Avg conviction: 3.6%. Net adding. First tracked at $149.83 (current +8.9% vs tracked).
Oakcliff Capital Partners has 7.3% in this stock
Benchmark comparison unavailable
Prices are approximate, based on 13F reported values (position value / shares), not actual cost basis. Data covers 17 tracked value-oriented funds. Holdings are reported quarterly with a ~45-day lag. Stock splits may affect share count comparisons. Returns are not annualized.
| Fund | % of Portfolio | Action |
|---|---|---|
| Oakcliff Capital Partners | 7.3% | Add |
| Citadel Advisors | 0.0% | Add |